Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › SOLSTICE (NCT06579105)

SOLSTICE (NCT06579105)

AZD5004 (ECC5004) · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
AZD5004 (ECC5004)
Population
t2d
Phase
2
Participants
406
Duration
26 weeks
Registry
NCT06579105

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
5 mg QD vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3t2d26406−2.9 % vs −1.7 %
Δ −1.2 pp
—−0.9 vs −0.1——————press release
15 mg QD vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3t2d26406−3.4 % vs −1.7 %
Δ −1.7 pp
—−1.1 vs −0.1——————press release
25 mg QD vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3t2d26406−4.0 % vs −1.7 %
Δ −2.3 pp
—−1.2 vs −0.1——————press release
50 mg QD (escalated every 2 weeks) vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3t2d26406−5.9 % vs −1.7 %
Δ −4.2 pp
—−1.4 vs −0.1——————press release
75 mg QD (escalated every 2 weeks) vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3t2d26406−7.7 % vs −1.7 %
Δ −6.0 pp
—−1.9 vs −0.1——37.0 vs 3.018.0 vs 1.0——press release
75 mg QD (escalated every 4 weeks) vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3t2d26406−7.0 % vs −1.7 %
Δ −5.3 pp
—−1.6 vs −0.1——————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (14)
  • 5 mg QD · hba1c · publication (abstract)
    change from baseline in HbA1c ranged between -0·91% (95% CI -1·25 to -0·58; 5 mg elecoglipron)
  • 5 mg QD · weight_eff · press release
    | -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
  • 15 mg QD · hba1c · press release
    | -0.9% | -1.1% | -1.2 | -1.4% | -1.9% | -1.6% | -0.2% | -1.3%
  • 15 mg QD · weight_eff · press release
    | -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
  • 25 mg QD · hba1c · press release
    | -0.9% | -1.1% | -1.2 | -1.4% | -1.9% | -1.6% | -0.2% | -1.3%
  • 25 mg QD · weight_eff · press release
    | -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
  • 50 mg QD (escalated every 2 weeks) · hba1c · press release
    | -0.9% | -1.1% | -1.2 | -1.4% | -1.9% | -1.6% | -0.2% | -1.3%
  • 50 mg QD (escalated every 2 weeks) · weight_eff · press release
    | -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
  • 75 mg QD (escalated every 2 weeks) · hba1c · publication (abstract)
    -1·88% (-2·23 to -1·53; 75 mg elecoglipron with every 2-week dose-escalation step) compared with -0·15% (-0·42 to 0·12) with placebo
  • 75 mg QD (escalated every 2 weeks) · weight_eff · press release
    | -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
  • 75 mg QD (escalated every 2 weeks) · nausea · press release, safety paragraph (SOLSTICE)
    In SOLSTICE, the most common adverse events with elecoglipron (75mg) compared to placebo were nausea (37%, 3%), constipation (29%, 4%), diarrhoea (21%, 15%) and vomiting (18%, 1%)
  • 75 mg QD (escalated every 2 weeks) · vomiting · press release, safety paragraph (SOLSTICE)
    In SOLSTICE, the most common adverse events with elecoglipron (75mg) compared to placebo were nausea (37%, 3%), constipation (29%, 4%), diarrhoea (21%, 15%) and vomiting (18%, 1%)
  • 75 mg QD (escalated every 4 weeks) · hba1c · press release
    | -0.9% | -1.1% | -1.2 | -1.4% | -1.9% | -1.6% | -0.2% | -1.3%
  • 75 mg QD (escalated every 4 weeks) · weight_eff · press release
    | -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: SOLSTICE (NCT06579105). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/solstice/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.